Biostem Technologies Inc. (BSEM)
OTC PINK OTC PINK Primary 
BioStem Technologies Q1 Earnings Call Highlights
BioStem Technologies OTCMKTS: BSEM said its first quarter of 2026 marked a major shift in its business model following a late-January acquisition that moved the company's focus from physician offices toward the hospital market.
BioStem Technologies, Inc. (BSEM) Q1 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Q1 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Reports Q1 Loss, Tops Revenue Estimates
BioStem Technologies, Inc. (BSEM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.17 per share a year ago.
BioStem Technologies Reports First Quarter 2026 Financial Results
POMPANO BEACH, Fla., May 14, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the first quarter ended March 31, 2026.
BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026
POMPANO BEACH, Fla., April 08, 2026 (GLOBE NEWSWIRE) — BioStem Technologies® (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing and commercialization of perinatal tissue allograft products, today announced its participation in the Symposium on Advanced Wound Care (SAWC) Spring meeting in Charlotte, NC, from April 8-12.
BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference
POMPANO BEACH, Fla., March 31, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference.
BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025
The Company continues its progression towards a Nasdaq uplisting POMPANO BEACH, FL, March 30, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies, Inc. (BSEM) Q4 2025 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Q4 2025 Earnings Call Transcript
BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
Strategic acquisition and strong margins help offset market pressures and position BioStem for renewed growth in 2026 POMPANO BEACH, FL, March 24, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., March 11, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference
POMPANO BEACH, Fla., February 20, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies Highlights Alignment with FDA's Openness to Bayesian Statistical Approaches in Clinical Research
POMPANO BEACH, Fla., February 3, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S.
